Works by Shuhui Dong


Results: 19
    1
    2
    3

    Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.

    Published in:
    BMC Medicine, 2025, v. 23, n. 1, p. 1, doi. 10.1186/s12916-025-03985-4
    By:
    • Jiang, Yaofei;
    • Bei, Weixin;
    • Wang, Lin;
    • Lu, Nian;
    • Xu, Cheng;
    • Liang, Hu;
    • Ke, Liangru;
    • Ye, Yanfang;
    • He, Shuiqing;
    • Dong, Shuhui;
    • Liu, Qin;
    • Zhang, Chuanrun;
    • Wang, Xuguang;
    • Xia, Weixiong;
    • Zhao, Chong;
    • Huang, Ying;
    • Xiang, Yanqun;
    • Liu, Guoying
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19